a n a ly s i s Subunits of mammalian SWI/SNF (mSWI/SNF or BAF) complexes have recently been implicated as tumor suppressors in human malignancies. To understand the full extent of their involvement, we conducted a proteomic analysis of endogenous mSWI/SNF complexes, which identified several new dedicated, stable subunits not found in yeast SWI/SNF complexes, including BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, BRD9 and SS18. Incorporating these new members, we determined mSWI/SNF subunit mutation frequency in exome and whole-genome sequencing studies of primary human tumors. Notably, mSWI/SNF subunits are mutated in 19 .6% of all human tumors reported in 44 studies. Our analysis suggests that specific subunits protect against cancer in specific tissues. In addition, mutations affecting more than one subunit, defined here as compound heterozygosity, are prevalent in certain cancers. Our studies demonstrate that mSWI/SNF is the most frequently mutated chromatinregulatory complex (CRC) in human cancer, exhibiting a broad mutation pattern, similar to that of TP53. Thus, proper functioning of polymorphic BAF complexes may constitute a major mechanism of tumor suppression.
Recent genome-wide sequencing efforts have provided unprecedented views of gene networks and are increasingly being used to identify biological pathways underlying complex diseases 1 . In particular, exome and whole-genome sequencing studies of human cancer have provided an opportunity to revisit the contributions of oncogenic genetic circuitries and networks, and, notably, these studies have repeatedly identified mutations in genes encoding subunits of polymorphic mSWI/SNF complexes. mSWI/SNF complexes are polymorphic assemblies of at least 14 subunits encoded by 28 genes, generating an extensive diversity of complexes with specialized functions in specific tissues [2] [3] [4] . Early studies indicated that the catalytic subunits SMARCA4 (BRG1) or SMARCA2 (BRM) are frequently inactivated in established cell lines. Reintroduction of BRG1 into cell lines lacking BRG1 or BRM resulted in Rb-dependent cell cycle arrest, leading to the speculation that they were tumor suppressors 5, 6 . Clear evidence that at least one mSWI/SNF subunit is indeed a tumor suppressor emerged when SMARCB1 (hSNF5) was found to be biallelically inactivated and to undergo loss of heterozygosity (LOH) in malignant rhabdoid tumors, an aggressive set of pediatric malignancies [7] [8] [9] [10] [11] . In addition, several studies reported frequent inactivation of SMARCA4, SMARCC1, SMARCD3, PBRM1, DPF2 and ARID1A in several tumor types, including breast, lung and colon carcinomas [12] [13] [14] [15] [16] [17] [18] [19] .
We report a proteomic analysis in parallel with biochemical investigations to determine the composition of endogenous mSWI/SNF complexes in various cell types. We identified several additional mSWI/SNF subunits that do not have homologs in the yeast SWI/ SNF complex. These data enabled us to perform a comprehensive meta-analysis of 44 exome and whole-genome sequencing studies to determine the contribution of mSWI/SNF gene mutations compared to those of other chromatin regulators as well as established tumor suppressors and oncogenes. Our analysis shows that mSWI/SNF complexes represent the most frequently mutated chromatin regulator in human cancer and thus substantiates and extends earlier evidence from genetic studies.
RESULTS

Identification of new, stable and dedicated mSWI/SNF complex subunits
We performed an affinity purification-mass spectrometry-based analysis of endogenous mSWI/SNF complexes in several primary cell types, including mouse embryonic stem (ES) cells, fibroblasts, neural progenitors and neurons, to better define the combinatorial assemblies of mSWI/SNF complexes and their associated proteins. This study was performed using an antibody specific to the C terminus of the Brg1 ATPase subunit, thereby allowing for rapid purification of the complexes after a single biochemical step 4, 20 . We recovered several new subunits, including Bcl7a, Bcl7b and Bcl7c and Bcl11a and Bcl11b, as well as Ss18 and Brd9. Peptide numbers and percent coverage for these proteins were comparable to those of Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy a n a ly s i s established mSWI/SNF complex subunits (Supplementary Table 1) . To determine the extent of dedication of these putative subunits to mSWI/SNF complexes, we performed density sedimentation analyses using a human T cell line. BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, and BRD9 sedimented exclusively with BRG1 and other mSWI/SNF complex subunits in glycerol gradients; these proteins were not associated with complexes of lower molecular weight, such as Polycomb repressive complexes PRC1 or PRC2 (detected with immunoblots for BMI1 or EzH2, respectively), nor did they migrate as free monomers (Fig. 1a and Supplementary Table 2) . In separate experiments, we noted that PBAF components BAF200 and BAF180 migrated with a much larger complex of about 4-5 MDa 3 and that only about 10% of these proteins were incorporated into the 2-MDa complexes (fractions [13] [14] [15] shown in Figure 1a . Hence, BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, and BRD9 are subunits of mSWI/SNF complexes rather than PBAF complexes. This is consistent with the specialized role of PBAF defined in vitro 21 .
The observation that subunits did not dissociate during the 16-h centrifugation necessary to perform the glycerol gradient analysis indicates that the complexes are stable and undergo relatively little subunit exchange. To independently assess the stability of the newly identified subunits within the complexes, we used urea denaturation, a strategy employed in early studies to define ribosomal subunits. We subjected CCRF-CEM T cell nuclear extracts to a range of urea concentrations before immunoprecipitation with antibody to BRG1. Notably, BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, and BRD9 were bound to the mSWI/SNF complex with stabilities greater than or equal to those of established subunits, including BAF47, BAF155 and BAF170 (Fig. 1b) , reflecting associations comparable to those of ribosomal subunits 22, 23 . In addition, reciprocal immunoprecipitations in human T cells using antibodies to the newly identified complex BAF45A,  BAF45D   SS18 BCL7A,  BCL7B,  BCL7C   BAF60A,  BAF60C   BRD9   BCL11A,  BCL11B   12 13 14 15 16 17 18 19 20 Fraction  3  2  1  4 5 6 7 8 9 10 11  BAF250A   BRG   BCL7A   BCL7B   BCL7C   BAF170  BAF155   BCL11B   BCL11A   BAF47   BMI1   EZH2   BRD9 10% Glycerol gradient 30% Ovarian clear-cell 6 8 75 Hematologic malignancies npg a n a ly s i s members pulled down known mSWI/SNF components (Fig. 1c) . These results establish BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, SS18 and BRD9 as dedicated, non-exchangeable subunits of the mSWI/SNF complex that are not simply associated proteins, as has been previously suggested by ourselves and others 3, 4, 24, 25 ( Fig. 1d) . Thus, the function of these proteins must be thought of as a critical aspect of the function of mSWI/SNF complexes.
mSWI/SNF complexes are the most highly mutated CRC
We performed an analysis of 44 published genome and/or exome sequencing studies to compare the mutational frequencies of the mSWI/SNF subunit genes to those of other CRCs as well as established tumor suppressors and oncogenes (Supplementary Table 3) . We determined the absolute number and overall frequency of missense, nonsense and insertion-deletion mutations in each established or new mSWI/SNF subunit gene (Supplementary 54 in which some tumor samples were expanded as xenografts or for a limited number of passages in culture were included (Supplementary Table 3 ). The mutation frequency for each gene was calculated as the number of mutations divided by the total number of cases (individuals with the cancer type) evaluated in one or more studies. The relative contribution of mutations in each mSWI/SNF complex gene to each cancer type is shown (Fig. 2a) .
Where applicable, we show the mutation frequencies calculated from validation studies ( Fig. 2a and Supplementary Table 5) . Finally, to calculate the frequency of mutation to the mSWI/SNF complex collectively, we divided the number of cases carrying a mutation in any mSWI/SNF subunit gene by the total number of cases in each cancer type (Fig. 2a, bottom) . By averaging these frequencies, we found that mSWI/SNF is mutated in 19.6% of all cancer types analyzed. ARID1A is the most frequently mutated of the mSWI/SNF subunit genes, with mutations occurring primarily in solid tumors. ARID1A mutations were present in 45.2% of endometrioid and clear-cell ovarian, 18.7% of gastric, 18.6% of bladder, 13.7% of hepatocellular, 9.4% of colorectal, 11.5% of melanoma, 8.2% of lung, 3.6% of pancreatic and 2.5% of breast cancers ( Fig. 2a and Supplementary Table 5 ). To address whether mutation of an mSWI/SNF subunit gene confers a selective advantage to a particular cancer, we compared the mutation frequency of each subunit gene to the background mutation rate (BMR), accounting for gene length (Fig. 2b, Supplementary Table 6 and Supplementary Note). We used the overall nonsynonymous BMR reported by each study or the number of nonsynonymous mutations divided by the total number of bases sequenced if the BMR was not reported. Our statistical analysis is therefore based on the BMR for each tumor type and is corrected for gene length (Supplementary Table 3 ).
We found that SMARCA4, ARID1A, ARID1B, ARID2 and PBRM1 each had mutation frequencies significantly higher than the BMR in studies from two or more cancer types (SMARCA4, P ≤ 1.6 × 10 −2 ; ARID1A, P ≤ 1.0 × 10 −2 ; ARID1B, P ≤ 4.4 × 10 −2 ; ARID2, P ≤ 4.7 × 10 −2 ; PBRM1, P ≤ 1.9 × 10 −2 ), which suggests that mutations to these genes are 'driver' rather than 'passenger' genetic lesions ( Fig. 2b and Supplementary Table 6 ). The significance of these mutation rates is particularly notable because ARID1A, ARID1B, ARID2 and PBRM1 had not been considered to be important contributors to oncogenesis before the advent of high-throughput sequencing. Several core mSWI/SNF subunits were infrequently mutated, including SMARCD1, SMARCD2 and SMARCD3, SMARCE1, PHF10, DPF1, DPF2 and DPF3 and ACTL6A and ACTL6B, consistent with previous observations. In addition, some subunits previously thought to have a role in tumorigenesis, such as SMARCC1 and SMARCC2 (refs. 15,76) were rarely mutated in primary tumors. The newly identified subunits BCL11B and BCL7A were frequently mutated in hematologic malignancies (Fig. 2c) . BCL11B was mutated in 5.7-12.7% of T cell acute lymphoblastic leukemias (T-ALLs), and BCL7A was mutated in 19.7% of non-Hodgkin lymphomas and 21.7% of multiple myelomas ( Fig. 2a and Supplementary Table 5 ). BCL11B and BCL7A were significantly mutated at frequencies above the BMR in these cancers (BCL11B, P ≤ 2.0 × 10 −7 ; BCL7A, P ≤ 1.3 × 10 −6 ), suggesting that mutation of these genes and subsequent loss of protein function might drive oncogenesis (Table 1 and Supplementary Table 6 ).
In addition to significant mutation frequencies in hematologic malignancies, several of the subunits newly identified in our biochemical studies were involved in chromosomal translocations, which are considered driving events in specific cancers. Translocations involving the SS18 subunit gene represent the hallmark of synovial sarcoma (SS18-SSX), observed in >95% of cases [77] [78] [79] . In addition, the t(5;14)(q35;q32.2) translocation involving BCL11B was present in 20-25% of pediatric 71 and up to 5% of adult T-ALL 80 cases and defines a molecular subset of this malignancy. BCL11A can also be involved in translocation 81 . To determine the consequences of translocations involving these new mSWI/SNF subunit genes in disease, we calculated the frequency with which the translocation of interest represented the sole genomic abnormality and thus a clear driving event (Fig. 2c) . We analyzed BCL11A translocations t(2;14)(p13;q32) and t(2;14)(p16;q32), the BCL11B translocation t(5;14)(q35;q32.2) and SS18 t(X;18) translocations and found that they represented the sole genomic abnormality in 24.4%, 38.7% and 28.7% of cases, respectively. These data indicate that translocations involving mSWI/SNF component genes, particularly the three genes encoding proteins shown to be new subunits in this analysis, contribute substantially to the impact of mSWI/SNF subunit alterations in human cancer 82 .
Frequency of chromatin-regulatory mutations in human cancers
Because mSWI/SNF subunits are dedicated to the mSWI/SNF complex and are thought to function collectively as a single multisubunit complex, we captured the propensity for mutation of the genes in the complex as a whole by considering the joint mutation frequency of mSWI/SNF components, including genes encoding newly identified subunits. We present the mutation frequency of the complex genes as the maximum-likelihood value of the mutation frequency relative to the BMR, based on the joint likelihood of mutations in the individual subunit genes (Fig. 3 and Supplementary Note). The overall mutation frequencies were greater than the BMR in 26 of 44 studies (mutation rate/BMR = 1.0-17.1), including in clear-cell ovarian, pancreatic, renal cell, hepatocellular, bladder, gastric, breast, glioma, medulloblastoma npg a n a ly s i s and hematologic malignancies (Fig. 3) . mSWI/SNF was significantly mutated in ten studies from this group (colorectal, P = 1.4 × 10 −4 ; clear-cell ovarian, P = 3.6 × 10 −8 ; renal cell, P = 2.7 × 10 −3 ; hepatocellular, 9.5 × 10 −3 ≤ P ≤ 4.7 × 10 −2 ; medulloblastoma, 1.4 × 10 −2 ≤ P ≤ 4.7 × 10 −2 ; acute myeloid leukemia, P = 2.8 × 10 −2 ; Burkitt lymphoma, 7.1 × 10 −3 ≤ P ≤ 1.5 × 10 −2 ), highlighting a potentially protective role of mSWI/SNF in the prevention of these cancers. mSWI/SNF complexes were mutated at frequencies at or below the BMR in colorectal carcinoma (one of two studies), squamous cell carcinoma of the head and neck, lung cancer and melanoma (Fig. 3) . Although these cancers have a high frequency of mSWI/SNF subunit gene mutations (Fig. 2a) , several cases were considered to be hypermutated and, therefore, high BMRs may inaccurately obscure the role of mSWI/SNF in the progression of these tumor types 26, [51] [52] [53] [54] [55] [56] [57] [58] [59] (Supplementary Fig. 1) . Figure 3 mSWI/SNF complexes are more frequently mutated than other chromatin-modifying complexes in human cancer. The mutation rate/BMR for 44 exome sequencing studies for mSWI/SNF, TIP60, SRCAP, INO80, ISWI, NURD, PRC1 and PRC2 complexes is graphed. Number refers to the reference for the publication; details are given in supplementary Table 3 . Statistically significant mutation rates are indicated with asterisks; *P < 0.05, **P < 0.001. The bar graphs under each complex name indicate the percentage of studies for which that complex was the most highly mutated complex of the eight examined. OCCC, ovarian clear-cell carcinoma; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; BL, Burkitt lymphoma. npg a n a ly s i s
Using a similar statistical approach, we compared the mutation rates of mSWI/SNF complex genes to those of genes in several other CRCs, including the TIP60, INO80, SRCAP, NURD, ISWI, PRC1 and PRC2 complexes (Fig. 3 and Supplementary Note) . mSWI/SNF was the most frequently mutated of the CRCs analyzed in 45.4% of the studies. PRC2 had the highest mutation rate in 15.9% of studies, which was significant in the hematologic malignancies non-Hodgkin lymphoma, diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma and T-ALL, in agreement with findings in previous studies [83] [84] [85] [86] . The SWI/SNF-like ATRX-DAXX complex has been shown to be highly mutated in pediatric glioblastoma multiforme 87, 88 and pancreatic neuroendocrine tumors 89 ; however, we found that it was infrequently mutated in the 44 studies included. Moreover, mSWI/SNF subunits were not mutated in these rare tumors, suggesting that ATRX-DAXX complex mutations are isolated and mutually exclusive with mSWI/SNF subunit gene mutations (data not shown). Our analysis indicates that genes encoding mSWI/SNF complex components possess significantly higher rates of mutation than the genes encoding other CRCs in human cancers, pointing to a specific mechanism underlying their role in tumor suppression.
Chromatin modifiers such as the HDAC and MLL families and EP300 have also been strongly implicated in cancer 90 . We thus compared the mutation rate of the most frequently mutated mSWI/SNF subunit gene in each study to the mutation rate of the most frequently mutated of the MLL genes (MLL1-MLL5), the most frequently mutated of the HDAC genes (HDAC1-HDAC11) or EP300 (Fig. 4  and Supplementary Table 7) . We represent the ratio of the mutation frequency of each chromatin-modifier gene relative to that of the mSWI/SNF subunit gene, with a ratio of <1 indicating that the peak mutation frequency of the mSWI/SNF gene was higher than that of the chromatin-modifier gene and a ratio of >1 indicating that the mutation frequency of the chromatin-modifier gene was higher (Fig. 4) . With few exceptions, the mSWI/SNF subunits were more frequently mutated than the other chromatin modifiers suggested to have important roles in tumorigenesis. The higher mutational prevalence of mSWI/SNF genes was statistically significant for 36.3%, 25% and 34.1% of the studies when compared to mutation rates in MLL genes (P ≤ 4.0 × 10 −2 ), HDAC genes (P ≤ 3.8 × 10 −2 ) and EP300 (P ≤ 1.76 × 10 −2 ), respectively, indicating a major role for mSWI/SNF perturbation in the development of human cancers.
Comparison to known tumor suppressors and oncogenes
To further estimate the relative impact of potential tumor suppressive functions of mSWI/SNF complexes, we compared the mutation rates of established tumor suppressors and oncogenes to that of the most frequently mutated mSWI/SNF subunit gene in each study (Fig. 5a,b and Supplementary Table 7) . We selected TP53, PTEN, CDKN2A, PIK3CA, KRAS and CTNNB1 for comparison on the basis of wellestablished evidence of their tumor suppressive and oncogenic functions. We limited our analysis to nonsynonymous coding mutations and did not include data on deletions or amplifications. Notably, mSWI/SNF subunits were more broadly mutated, with mutations occurring in multiple malignancies of varying tissue origins, than any other tumor suppressor or oncogene analyzed, with the exception of TP53. Tumor suppressors and oncogenes analyzed here were mutated with high frequency in specific cancers rather than across several tumor types. For example, PTEN was more highly mutated than the most frequently mutated mSWI/SNF subunit gene in serous ovarian cancer and glioma, CDKN2A was more highly mutated in melanoma and pancreatic, lung and squamous cell carcinomas, PIK3CA was more highly mutated in colorectal, breast and head and neck squamous cell cancers, KRAS was more highly mutated in colorectal, lung and pancreatic cancers, and CTNNB1 was more highly mutated in hepatocellular and medulloblastoma cancers (Fig. 5a,b) . These profiles highlight the specificity of these tumor suppressors and oncogenes in driving particular cancers; mSWI/SNF subunit genes by contrast were significantly mutated in a range of cancers (Fig. 3) , suggesting an extensive role of tumor suppression that protects fundamental cellular functions.
Compound heterozygosity of mSWI/SNF subunit genes
Whereas prototypical tumor suppressors often undergo LOH, many mSWI/SNF subunit gene mutations analyzed in primary tumors were found to be heterozygous 29, 72 . We hypothesized that heterozygous mutations in more than one mSWI/SNF subunit gene might result in a compound heterozygous phenotype because of the dedicated nature Figure 4 mSWI/SNF subunit genes are more frequently mutated than EP300, MLL and HDAC family genes. The ratio of the mutation frequency of EP300, the most frequently mutated MLL family member or the most frequently mutated HDAC member was plotted relative to that of the most frequently mutated mSWI/SNF subunit for each study. Ratios of <1 indicate that the peak mutation frequency of the mSWI/SNF gene is higher than that of the chromatin modifier; ratios of >1 indicate that the mutation frequency of the chromatin modifier is higher. Statistically significant ratios are indicated; *P < 0.05, **P < 0.001. Number refers to the reference for the publication; details are given in supplementary Table 3 .
npg a n a ly s i s of mSWI/SNF subunits within the complex and might explain why many of the tumors did not have homozygous inactivation affecting a single subunit. We analyzed cases carrying more than one mutation or deletion of any mSWI/SNF subunit gene and found that up to 50% (mean of 14.3%) of cases had compound heterozygosity in certain cancer types (Fig. 6a) . We observed a particularly high occurrence of this phenomenon in squamous cell carcinoma (50%), renal cell carcinoma (28%) and clear-cell ovarian carcinoma (25%). The limited number of data points precluded us from defining a single pairing that occurred with higher frequency than others, although more than a third (36.8%) of the compound heterozygous cases were noted to have one or more mutations in ARID1A (Fig. 6a) . The prevalence of cases with multiple mSWI/SNF subunit gene mutations suggests that compound heterozygosity might have functional repercussions, which could contribute to human malignancy. In addition, because mutations that were present in the adjacent normal tissue were often not reported in the included studies, we may have underestimated the frequency of compound heterozygosity.
mSWI/SNF and TP53 mutations are frequently mutually exclusive
We assessed the frequency with which mSWI/SNF gene mutations occur together with mutations in other known oncogene or tumor suppressor pathways to determine which pathways are sufficient to cause transformation in the setting of an mSWI/SNF subunit gene mutation. For example, ARID1A mutations were shown to be mutually exclusive with TP53 mutations but coincident with PIK3CA T-ALL   26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68 T-ALL   26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68 69 Lung BL Figure 5 Mutations in mSWI/SNF subunit genes occur in a broad spectrum of cancer types. The ratio of the mutation frequency of the tumor suppressors TP53, PTEN and CDKN2A (a) and the oncogenes PIK3CA, KRAS and CTNNB1 (b) was plotted relative to that of the most frequently mutated mSWI/SNF subunit. Ratios of <1 indicate that the peak mutation frequency of the mSWI/SNF gene is higher than for the tumor suppressor or oncogene; ratios of >1 indicate that the mutation frequency of the tumor suppressor or oncogene is higher. Statistically significant ratios are indicated; *P < 0.05, **P < 0.001. Number refers to the reference for the publication; details are given in supplementary Table 3 .
npg a n a ly s i s and CTNNB1 mutations in clear-cell ovarian carcinoma 29, 72 . We calculated the mutual exclusivity of TP53 mutations and the most highly mutated mSWI/SNF subunit genes, namely ARID1A, SMARCA4 or ARID2, in solid tumors (Fig. 6b) . Although mutations to mSWI/SNF subunit genes and TP53 were not strictly mutually exclusive, there was a tendency toward mutual exclusivity in colorectal (odds ratio, OR = 0.217), clear-cell ovarian (OR = 0.077), gastric (OR = 0.215), hepatocellular (OR = 0.544 for ARID1A, OR = 0.341 for ARID2), medulloblastoma (OR = 0.493) and breast (OR = 0.594) cancers, which was statistically significant for colorectal (OR = 0.217, 95% confidence interval (CI) = 0.07-0.68; P = 0.0043) and gastric (OR = 0.215, 95% CI = 0.091-0.51; P = 0.0002) cancers. In contrast, all cases with an ARID1A mutation in serous ovarian cancer, glioma and squamous cell carcinoma or a SMARCA4 mutation in pancreatic cancer also had a mutation in TP53, perhaps reflecting a requirement for loss of TP53 function in these cancers (Fig. 6b) . This dichotomy might also reflect the fact that ARID1A and mSWI/SNF complex genes are not significantly mutated in these cancers and suggest that these mutations are instead merely passenger mutations to a TP53 driver mutation ( Fig. 3 and Supplementary Table 6 ). Despite a limited cohort of cases, we similarly observed that mutations in mSWI/SNF subunit genes and PTEN in colorectal and serous ovarian carcinomas tended to be mutually exclusive, which was significant for ARID1A and PTEN in colorectal cancer (OR = 0.303, 95% CI = 0.110-0.838; P = 0.0121) (Supplementary Fig. 2 ). In contrast, mSWI/SNF subunit gene mutations seemed to occur together with mutations in some oncogenes. ARID1A and CTNNBI mutations were coincident in colorectal (OR = 4.545, 95% CI = 1.326-15.58; P = 0.0283) and hepatocellular (OR = 2.667, 95% CI = 1.075-6.618; P = 0.0306) carcinomas, and SMARCA4 and CTNNBI mutations occurred together in medulloblastoma (OR = 8.819, 95% CI = 3.431-22.67; P < 0.0001), in keeping with observations that SMARCA4 mutations are present in medulloblastomas driven by CTNNB1 and MYC but not by SHH ( Supplementary  Fig. 2 ) 48, 49 . Similarly, mutations in ARID1A and PIK3CA were paired in clear-cell ovarian cancer, as noted previously (OR = 7.000, 95% CI = 1.590-30.81; P = 0.0106) 29 and showed overlap in colorectal and breast carcinomas (Supplementary Fig. 2 ). Thus, mSWI/SNF complex gene mutations represent a substantial contribution to oncogenesis, which we demonstrate is independent of loss of the tumor suppressors TP53 and PTEN and potentially cooperative with oncogenic mutations such as those occurring in CTNNB1 and PIK3CA.
DISCUSSION
We present a comprehensive proteomic and biochemical analysis of endogenous mSWI/SNF complexes in several non-transformed cell types, which facilitated a complete bioinformatic assessment of mutational frequencies in mSWI/SNF components in human cancers. Efforts to identify mSWI/SNF complex components have generally used overexpressed, tagged proteins in transformed cell lines, in which stoichiometric relationships are disturbed. Our studies allowed us to accurately determine the subunit composition of endogenous mSWI/SNF complexes, identifying several new subunits as well as interacting proteins lacking the dedicated, non-exchangeable features of a subunit. We find that mSWI/SNF complexes have approximately the same stability as the ribosome 22, 91, 92 , as determined using ureabased denaturation methods. Hence, the functions of BCL7A, BCL7B and BCL7C, BCL11A and BCL11B, BRD9 and SS18, similar to those of established mSWI/SNF subunits, should be considered in the context of mSWI/SNF complex function. Notably, these subunits, as well as ARID1A, ARID1B and ARID2, PHF10, DPF1, DPF2 and DPF3, PBRM1 (BAF180), β-actin and SMARCE1 (BAF57), are not present in the yeast SWI/SNF complex, although proteins homologous to npg a n a ly s i s PBRM1, SMARCE1 and β-actin are found in the yeast RSC and SWR1 complexes 93, 94 . Thus, they likely perform some function related to evolutionarily newer strategies of chromatin regulation, such as greater complexity and/or specificity in mSWI/SNF complex targeting, Polycomb-mediated repression or DNA methylation. These differences compared to yeast SWI/SNF led us to refer to the complexes as BAF rather than mSWI/SNF to prevent inappropriate extrapolation 95, 96 ; however, here, we used mSWI/SNF in accordance with common usage. Our proteomic studies enabled a comprehensive examination of mSWI/SNF gene mutation frequencies in tumors from 44 wholegenome and exome sequencing studies. mSWI/SNF complexes are mutated at frequencies above the BMR in the majority of studies, which spanned a wide spectrum of solid and hematologic tumors. However, there are also tumor types in which mSWI/SNF is frequently mutated but does not reach significance owing to insufficient numbers of cases and hypermutation. Nevertheless, the breadth of mSWI/SNF involvement uncovered in this analysis is notable and resembles that of TP53, albeit with lower mutation frequencies, suggesting that mSWI/SNF prevents tumorigenesis through basic cell biological functions.
A second point emerging from our analysis is that specific tissues are protected from malignancy by the function of specific subunits. Examples of a predominance of one subunit over its polymorphic partner suggests that certain complex assemblies carry out the tumor suppressive role of mSWI/SNF. For example, ARID1A, ARID1B and ARID2 are mutually exclusive subunits occupying one position in the complex, and the corresponding genes are mutated with different frequencies in different cancer types. Similarly, SMARCA4 and SMARCA2 have similar ATPase activity, but the SMARCA2 gene is rarely mutated in cancer, whereas SMARCA4 seems to be the second most frequently mutated subunit gene (Fig. 2a) . Cellular context also seems to have an important role; for example, although SMARCA4 is ubiquitously expressed, mutations in SMARCA4 occur in only specific cancer types. Likewise, BCL11B and BCL7A are mutated in hematologic malignancies but rarely in solid tumors. Notably, the subunits of a specialized mSWI/SNF complex found only in postmitotic neurons (nBAF) 3, [97] [98] [99] are rarely mutated in any of the cancers examined. Finally, SMARCB1 (hSNF5) is biallelically inactivated in nearly all malignant rhabdoid tumors but is rarely mutated in other cancer types 100, 101 . This indicates that the apparent broad general role of the complexes in tumor suppression is likely related to the specific functions of different polymorphic assemblies in different tissues.
At present, there is little knowledge of how the individual subunits function within polymorphic complexes. It is generally assumed that the function of the ATPase subunits is to promote nucleosome mobility and that the function of the PHD domains, bromodomains, chromodomains and DNA-binding domains is to target the complex to specific genetic loci; however, these functions have yet to be demonstrated conclusively. The newly identified subunits BCL11A and BCL11B are zinc finger-containing transcriptional repressors that are critical for the development of the erythroid and lymphoid lineages 102, 103 , whereas little is known of the function of SS18 and the BCL7 family members. Because mSWI/SNF is known to directly repress transcription by binding to about 15,000 islands across the genome 104 , one can speculate that aberrant chromatin binding, mistargeting or loss of ATPase activity might underlie the role(s) of mutations affecting different mSWI/SNF subunits in human malignancy. Alternatively, loss of hSNF5 results in enhanced PRC2-mediated repression of critical repressors of cell proliferation such as INK4A-ARF 105 . Ezh2 and Smarcb1 (Snf5) double mutants are completely rescued from hSNF5 inactivation-driven tumorigenesis, strongly implicating the ability of mSWI/SNF to evict or oppose PRC2. Indeed, loss of Smarca4 also results in global increases in PRC2 binding and histone H3 lysine 27 trimethylation (H3K27me3) deposition at mSWI/SNF-binding sites in mouse ES cells 104 .
On the basis of the dedicated nature of mSWI/SNF complex subunits, we hypothesized that an otherwise passenger heterozygous mutation in one subunit gene paired with a heterozygous mutation in a gene encoding another subunit could result in loss of mSWI/SNF tumor suppressive function. We think of this as a form of compound heterozygosity. For example, we found that many tumors had an ARID1A or SMARCA4 driver mutation paired with a mutation in an infrequently mutated subunit gene (Fig. 6a) . Using the MutationAssessor platform, we found that most of these passenger mutations are predicted to be deleterious and thus could indeed further disable the mSWI/SNF complex in the context of compound heterozygosity. These mutational pairings may confer a unique loss of function, or they may be less detrimental to cells and thus selected over homozygous inactivation of ARID1A or SMARCA4. Greater sample size will help determine whether mSWI/SNF compound heterozygosity is a driving mechanism in tumorigenesis and define oncogenic pairings.
Our studies support the previously expressed notion that mSWI/ SNF subunits are tumor suppressors rather than oncogenes 5, 7 . Indeed, the fact that mSWI/SNF subunit gene mutations are generally exclusive from TP53 and PTEN mutations suggests an analogous role for mSWI/SNF complexes in tumor suppression ( Fig. 6b  and Supplementary Fig. 2) . However, specific mutations or translocations affecting mSWI/SNF subunit genes may produce gainof-function properties that result in a specific mSWI/SNF complex becoming oncogenic. Future studies will be necessary to define the mechanism(s) that underlie the frequent mutation of mSWI/SNF subunit genes in human cancer. Although tumor suppressors are often considered difficult therapeutic targets, detailed mechanistic studies might elucidate unexpected avenues for treatment of this broad class of human cancers.
